查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1571496

重組 DNA 技術市場規模、佔有率和趨勢分析報告：按產品、組件、應用、最終用途和細分市場進行預測，2024-2030 年

Recombinant DNA Technology Market Size, Share & Trends Analysis Report By Product (Medical, Non-medical), By Component (Expression System), By Application, By End Use, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

重組 DNA 技術市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計2024年至2030年全球重組DNA技術市場規模將以5.4%的複合年成長率成長，2030年將達到10,671億美元。

重組人類胰島素在治療糖尿病方面的成功引發了許多其他重組療法和藥物的開發。這導致了重組DNA（rDNA）技術的巨大成功。這項技術為闡明該疾病與其有效治療之間的差距提供了重要視角。

該技術在動物產品開發、基因改造作物開發、生物農藥和生質燃料生產以及基因治療中的廣泛和成功應用預計將在預測期內推動該技術的採用。

基因改造 (GM) 產品的使用，例如使用 rDNA 方法開發的基因改造動物，已被證明對於加速醫學研究至關重要。此外，還進行了 3,000 多項科學研究來評估基因改造產品的安全性及其對人類健康和環境的影響。

此外，對疾病治療的有效治療劑的需求不斷增加，使得重組蛋白生產能力的需求增加了數倍。上述事實表明，該領域的技術進步正在推動成長。

據包括孟山都公司在內的基因改造作物支持者稱，基改作物是近年來應用最迅速、最廣泛的農業創新之一。預計這將促進 rDNA 技術在非傳統應用中的採用。

重組 DNA 技術市場報告亮點

  • 2023年，醫用rDNA產品將在銷售佔有率中佔據主導地位。
  • 這是因為胰島素的商業性成功鼓勵公司進一步開發重組藥物。
  • 哺乳動物表現系統因其高效的瞬時和穩定的表達能力而獲得了最大的市場佔有率。
  • 使用哺乳動物表現系統改進的高產量培養基也支持了這一佔有率。
  • 健康和疾病領域佔銷售額的最大佔有率。
  • 基因治療、抗體生產、藥物代謝研究、重組治療和疫苗開發被認為是該技術在人類醫療保健管理中的主要應用。
  • 重組DNA技術市場包括各種最終用途部門，例如製藥和生物技術公司、學術和研究機構以及其他工業實體。
  • 從最終用途來看，由於大量生物製藥公司採用 rDNA 產品，製藥和生物技術公司估計是最大的細分市場。
  • 由於存在有關核准基因改造療法和產品的有效法規，北美佔據了最大佔有率。
  • 亞太地區預計將成為成長最快的區域市場。
  • 與西方國家相比，在印度等亞洲國家進行臨床試驗的成本相對較低。因此，世界上許多生物製藥開發公司正在向該地區擴張。
  • 百健 (Biogen)、安進 (Amgen)、禮來 (Eli Lilly)、孟山都 (Monsanto)、諾華 (Novartis) 和羅氏 (F. Hoffmann-La Roche) 是在該地區營運的主要企業。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第 3 章重組 DNA 技術市場變數、趨勢與範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 重組DNA技術市場分析工具
    • 波特的分析
    • PESTEL分析

第4章 重組DNA技術市場：產品評估與趨勢分析

  • 細分儀表板
  • 重組 DNA 技術市場：2023 年與 2030 年產品變異分析
  • 醫療保健
  • 非醫療的

第5章重組DNA技術市場：成分估計與趨勢分析

  • 細分儀表板
  • 重組 DNA 技術市場：成分變異分析，2023 年和 2030 年
  • 表達系統
  • 克隆載體

第6章 重組DNA技術市場：應用預估及趨勢分析

  • 細分儀表板
  • 重組 DNA 技術市場：2023 年與 2030 年應用變異分析
  • 食品和農業
  • 健康與疾病
    • 人類
    • 動物
  • 其他用途

第 7 章 重組 DNA 技術市場：最終用途估計與趨勢分析

  • 細分儀表板
  • 重組 DNA 技術市場：最終用途變異分析，2023 年和 2030 年
  • 生物技術和製藥公司
  • 學術和政府研究機構
  • 其他用途

第8章重組DNA技術市場：區域估計與趨勢分析

  • 2023 年及 2030 年重組 DNA 技術市場佔有率（按地區）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Pfizer Inc.
    • Sanofi
    • New England Biolabs
    • GlaxoSmithKline plc
    • GenScript
    • Thermo Fisher Scientific Inc.
    • Biogen Inc.
    • Merck &Co., Inc.
    • Amgen Inc.
    • Monsanto Company
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • Eli Lilly and Company
簡介目錄
Product Code: GVR-1-68038-872-5

Recombinant DNA Technology Market Growth & Trends:

The global recombinant DNA technology market size is expected to reach USD 1,067.1 billion by 2030, expanding at a CAGR of 5.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. The success of genetically engineered human insulin in diabetes treatment has triggered the development of many other recombinant therapeutics and drugs. This has translated to the huge success of Recombinant DNA (rDNA) technology. This technology has offered significant prospects for elucidating the gap between disease and its effective treatment.

Widespread successful application of this technique in veterinary product development, genetically modified crop development, biopesticides & biofuel production, and gene therapy, are expected to spur the adoption of this technology throughout the forecast period.

The use of Genetically Modified (GM) products, such as GM animals, developed using the rDNA method are found to be indispensable to accelerate medical research. Furthermore, more than 3000 scientific studies have been carried out to assess GM product safety in context to its impact on human health and the environment.

In addition, there is a rising need to improve the recombinant proteins' production capacity by several folds, owing to an increase in demand for effective therapeutics for disease treatment. The aforementioned fact pronounces the technological advances in this sector thus driving growth.

As per Monsanto and other proponents of GM crops, genetic engineering is one of the fastest and widely adopted agricultural innovations over the past few years. This, in turn, is expected to bolster the adoption of rDNA technology for non-traditional applications.

Recombinant DNA Technology Market Report Highlights:

  • Medical rDNA products dominated the share in 2023 in terms of revenue generation.
  • This can be attributed to the commercial success of insulin which has prompted firms for further development of recombinant drugs.
  • Owing to efficient transient and stable expression capabilities, mammalian expression system captured the largest share.
  • This share is also supported by the improvements in media for high yield using a mammalian expression system.
  • Health & disease accounted with the largest share in terms of revenue.
  • Gene therapy, antibodies production, drug metabolism investigation, recombinant therapeutic & vaccine development are recognized as major applications of this technology in human healthcare management.
  • Various end-use segments served by this recombinant DNA technology market encompass pharmaceutical & biotech entities, academic & research institutes, and other industrial entities.
  • End-use wise, pharmaceutical and biotechnology firms are estimated to be the largest segment owing to the presence of a substantial number of biopharma entities that have adopted rDNA products.
  • North America held the largest share owing to the presence of effective regulations pertaining to the approval of recombinant therapeutics as well as GM products.
  • Asia Pacific is expected to emerge as the fastest growing regional market.
  • Conducting clinical trials in Asian countries such as India is relatively less expensive compared to western countries. This has resulted in the migration of several global biopharmaceutical developers towards this region.
  • Biogen; Amgen Inc., Eli Lilly and Company, Monsanto Company, Novartis AG, and F. Hoffmann-La Roche Ltd are some of the major companies operating in this space.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Recombinant DNA Technology Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Billion)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Recombinant DNA Technology Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Recombinant DNA Technology Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Recombinant DNA Technology Market: Product Movement Analysis, 2023 & 2030 (USD Billion)
  • 4.3. Medical
    • 4.3.1. Medical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.2. Therapeutic Agent
      • 4.3.2.1. Therapeutic Agent Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.3. Human Protein
      • 4.3.3.1. Human Protein Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.4. Vaccine
      • 4.3.4.1. Vaccine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.4. Non-medical
    • 4.4.1. Non-medical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.2. Biotech Crops
      • 4.4.2.1. Biotech Crops Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.3. Specialty Chemicals
      • 4.4.3.1. Specialty Chemicals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.4. Other Non-medical Products
      • 4.4.4.1. Other Non-medical Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Recombinant DNA Technology Market: Component Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Recombinant DNA Technology Market: Component Movement Analysis, 2023 & 2030 (USD Billion)
  • 5.3. Expression System
    • 5.3.1. Expression System Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.3.2. Mammalian
      • 5.3.2.1. Mammalian Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.3.3. Bacteria
      • 5.3.3.1. Bacteria Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.3.4. Yeast
      • 5.3.4.1. Yeast Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.3.5. Baculovirus / Insect
      • 5.3.5.1. Baculovirus / Insect Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.3.6. Other Expression Systems
      • 5.3.6.1. Other Expression Systems Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.4. Cloning Vector
    • 5.4.1. Cloning Vector Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Recombinant DNA Technology Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Recombinant DNA Technology Market: Application Movement Analysis, 2023 & 2030 (USD Billion)
  • 6.3. Food & Agriculture
    • 6.3.1. Food & Agriculture Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.4. Health & Disease
    • 6.4.1. Health & Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.4.2. Human
      • 6.4.2.1. Human Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.4.3. Animal
      • 6.4.3.1. Animal Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.5. Other Applications
    • 6.5.1. Other Applications Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Recombinant DNA Technology Market: End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Recombinant DNA Technology Market: End Use Movement Analysis, 2023 & 2030 (USD Billion)
  • 7.3. Biotechnology and Pharmaceutical Companies
    • 7.3.1. Biotechnology and Pharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4. Academic & Government Research Institutes
    • 7.4.1. Academic & Government Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5. Other End Uses
    • 7.5.1. Other End Uses Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Recombinant DNA Technology Market: Regional Estimates & Trend Analysis

  • 8.1. Recombinant DNA Technology Market Share, By Region, 2023 & 2030 (USD Billion)
  • 8.2. North America
    • 8.2.1. North America Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.2.2. U.S.
      • 8.2.2.1. U.S. Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.2.3. Canada
      • 8.2.3.1. Canada Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.2.4. Mexico
      • 8.2.4.1. Mexico Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.3. Europe
    • 8.3.1. Europe Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.2. UK
      • 8.3.2.1. UK Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.3. Germany
      • 8.3.3.1. Germany Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.4. France
      • 8.3.4.1. France Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.5. Italy
      • 8.3.5.1. Italy Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.6. Spain
      • 8.3.6.1. Spain Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.7. Denmark
      • 8.3.7.1. Denmark Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.8. Sweden
      • 8.3.8.1. Sweden Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.9. Norway
      • 8.3.9.1. Norway Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.2. Japan
      • 8.4.2.1. Japan Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.3. China
      • 8.4.3.1. China Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.4. India
      • 8.4.4.1. India Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.5. South Korea
      • 8.4.5.1. South Korea Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.6. Australia
      • 8.4.6.1. Australia Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.7. Thailand
      • 8.4.7.1. Thailand Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5. Latin America
    • 8.5.1. Latin America Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.2. Brazil
      • 8.5.2.1. Brazil Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.3. Argentina
      • 8.5.3.1. Argentina Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6. Middle East and Africa
    • 8.6.1. Middle East and Africa Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.2. South Africa
      • 8.6.2.1. South Africa Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Saudi Arabia Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.4. UAE
      • 8.6.4.1. UAE Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.5. Kuwait
      • 8.6.5.1. Kuwait Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis by Key Market Participants
  • 9.2. Company Categorization
  • 9.3. Company Heat Map Analysis
  • 9.4. Company Profiles
    • 9.4.1. Pfizer Inc.
      • 9.4.1.1. Participant's Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Recent Developments/Strategic Initiatives
    • 9.4.2. Sanofi
      • 9.4.2.1. Participant's Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Recent Developments/Strategic Initiatives
    • 9.4.3. New England Biolabs
      • 9.4.3.1. Participant's Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Recent Developments/Strategic Initiatives
    • 9.4.4. GlaxoSmithKline plc
      • 9.4.4.1. Participant's Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Recent Developments/Strategic Initiatives
    • 9.4.5. GenScript
      • 9.4.5.1. Participant's Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Recent Developments/Strategic Initiatives
    • 9.4.6. Thermo Fisher Scientific Inc.
      • 9.4.6.1. Participant's Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Recent Developments/Strategic Initiatives
    • 9.4.7. Biogen Inc.
      • 9.4.7.1. Participant's Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Recent Developments/Strategic Initiatives
    • 9.4.8. Merck & Co., Inc.
      • 9.4.8.1. Participant's Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Recent Developments/Strategic Initiatives
    • 9.4.9. Amgen Inc.
      • 9.4.9.1. Participant's Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Recent Developments/Strategic Initiatives
    • 9.4.10. Monsanto Company
      • 9.4.10.1. Participant's Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Recent Developments/Strategic Initiatives
    • 9.4.11. F. Hoffmann-La Roche Ltd
      • 9.4.11.1. Participant's Overview
      • 9.4.11.2. Financial Performance
      • 9.4.11.3. Product Benchmarking
      • 9.4.11.4. Recent Developments/Strategic Initiatives
    • 9.4.12. Novartis AG
      • 9.4.12.1. Participant's Overview
      • 9.4.12.2. Financial Performance
      • 9.4.12.3. Product Benchmarking
      • 9.4.12.4. Recent Developments/Strategic Initiatives
    • 9.4.13. Eli Lilly and Company
      • 9.4.13.1. Participant's Overview
      • 9.4.13.2. Financial Performance
      • 9.4.13.3. Product Benchmarking
      • 9.4.13.4. Recent Developments/Strategic Initiatives